Clinical Trials Directory

Trials / Completed

CompletedNCT02772718

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
20 (actual)
Sponsor
XOMA (US) LLC · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and clinical pharmacology of XOMA 358 in patients with hypoglycemia after gastric bypass surgery.

Conditions

Interventions

TypeNameDescription
DRUGXOMA 358 single dose level AXOMA 358 single dose level A administered by intravenous infusion
DRUGXOMA 358 single dose level BXOMA 358 single dose level B administered by an intravenous infusion
DRUGXOMA 358 single dose level CXOMA 358 single dose level C administered by an intravenous infusion
DRUGXOMA 358 multiple dose level 1XOMA 358 multiple dose level 1 administered by an intravenous infusion

Timeline

Start date
2016-04-01
Primary completion
2021-05-01
Completion
2021-05-01
First posted
2016-05-13
Last updated
2021-05-21

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02772718. Inclusion in this directory is not an endorsement.